NCT01591421 - P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic/Advanced RAS-Wild Type Colorectal Cancer. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 6, 2012

Primary Completion Date

September 30, 2015

Study Completion Date

November 12, 2019

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG

BKM120

PO; Once daily starting day 1 cycle 1, or 5 out of 7 days every week.

DRUG

Panitumumab

IV; Every two weeks starting day 1 cycle 1 (i.e. day 1 and 15 each 28 day cycle)

Trial Locations (3)

BCCA - Vancouver Cancer Centre, Vancouver

Ottawa Hospital Research Institute, Ottawa

Univ. Health Network-Princess Margaret Hospital, Toronto